Clinical Trials Logo

Stage I Renal Cell Cancer clinical trials

View clinical trials related to Stage I Renal Cell Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06432036 Not yet recruiting - Clinical trials for Stage II Renal Cell Cancer

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

Start date: January 1, 2025
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial tests the safety, side effects and effectiveness of radioembolization with yttrium-90 (Y-90) in patients with early stage renal cell carcinoma. Y-90 is a radioactive chemical that is incorporated into millions of very tiny glass spheres. These spheres are injected into the artery that feeds the cancer. This process is called radioembolization. Y-90 radioembolization may be a safe and effective treatment for patients with early stage renal cell carcinoma.